PFE Pfizer, Inc. $PFE Company Overview
Stock Message Board http://investorshangout.com/search?q=PFE&...mp;yt1=Go!
Last Updated: Sunday, March 30, 2014 9:21:01 PM
Pfizer, Inc. PFE Current Price and Quotes
Last Price 31.88
Previous Close 32.10 Open 32.20
Daily Range 32.48 - 31.74 52wk Range 32.96 - 27.12
Volume 21,969,900 Dividend 1.04
Average Vol (3m) 26,844,396 Yield 3.2622
Pfizer, Inc. PFE
Company Information
235 East 42nd Street
New York, NY 10017
Website: http://www.pfizer.com
Phone: (212) 573-2323
Pfizer, Inc. PFE
Not Available
Pfizer, Inc. PFE
Financial Reportings and Disclosures
Reporting Status U.S. Reporting: SEC Filer
Latest Report Dec 31, 2013 10-K
CIK 0000078003
Fiscal Year End 12/31
OTC Marketplace Not Available
Profile Data
SIC - Industry Classification Not Available
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Service Providers
Auditor/Accountant
Not Available
Legal Counsel
Not Available
Investor Relations Firm
Not Available
Pfizer, Inc. PFE
PFE Security Details
Share Structure
Market Value1 $199,338,758,462 a/o Mar 28, 2014
Shares Outstanding 6,382,925,343 a/o Feb 21, 2014
Float Not Available
Authorized Shares Not Available
Par Value 0.05
Shareholders
Shareholders of Record 231,737 a/o Feb 29, 2008
Corporate Actions
Ex. Date Record Date Pay Date
Dividend () Aug 14, 2002 Aug 16, 2002 Sep 05, 2002
Security Notes
Capital Change=shs increased by 2 for 1 split. Ex-date=07-03-95. Rec date=06-01-95. Pay date=06-30-95
Latest Secondary Issue=11-72, 703,447 shs at $43 by Lazard Freres & Co. et al.
Par Changed=10 cents to 5 cents. Basis: 2 for 1 split. Ex-date=07-03-95. Rec date=06-01-95. Pay date=06-30-95
Capital Change=Capital Change=shs increased by 3 for 1 split. . Ex-date=07/01/1999. Rec date=06/02/1999. Pay date=06/30/1999.
Short Selling Data
Short Interest (%)
Significant Failures to Deliver No
Transfer Agent(s)
Pfizer, Inc. PFE Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 51,584,000 54,657,000 61,035,000 65,165,000
Cost of Revenue 9,586,000 9,821,000 12,500,000 14,788,000
Gross Profit 41,998,000 44,836,000 48,535,000 50,377,000
Operating Expenses
Research and Development 6,678,000 7,482,000 8,681,000 9,483,000
Sales, General and Admin. 14,355,000 15,171,000 17,581,000 18,973,000
Non-Recurring Items 1,182,000 1,810,000 2,841,000 3,145,000
Other 4,599,000 5,109,000 5,465,000 5,364,000
Operating Income 15,184,000 15,264,000 13,967,000 13,412,000
Income From Continuing Operations
Add'l Income/Expense Items 532,000 (4,022,000) (2,486,000) (3,941,000)
Earnings Before Interest and Tax 15,716,000 11,242,000 11,481,000 9,471,000
Interest Expense - - - -
Earnings Before Tax 15,716,000 11,242,000 11,481,000 9,471,000
Income Tax 4,306,000 2,221,000 3,621,000 1,153,000
Minority Interest 69,000 28,000 40,000 31,000
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations 11,410,000 9,021,000 7,860,000 8,318,000
Non Recurring Events
Discontinued Operations 10,662,000 5,577,000 2,189,000 (30,000)
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 22,003,000 14,570,000 10,009,000 8,257,000
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 22,003,000 14,570,000 10,009,000 8,257,000
Pfizer, Inc. PFE Recent News
Mar 28, 2014 Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium(R) 24HR
Mar 28, 2014 Technical Summary on Active Stocks -- Research on Cisco Systems, Pfizer, Vale, and Advanced Micro Devices
Mar 28, 2014 Positive Opinions, Presentation Schedules of Investigational Data, Clinical Study Results, and Stock Price Movements - Analyst Notes on Johnson & Johnson, Merck, Pfizer, Amgen, and Allergan
Mar 27, 2014 In A Subanalysis, The Benefits Of Eliquis(R) (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control(1)
Mar 27, 2014 Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study(1)
Mar 26, 2014 Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN(R) In Very Young Children Born Small For Gestational Age
Mar 25, 2014 Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts
Mar 25, 2014 The Zacks Analyst Blog Highlights:Bristol-Myers Squibb, Pfizer, Alexion Pharmaceuticals, Gilead Sciences and AGCO
Mar 25, 2014 Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI(R) (crizotinib) Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Mar 25, 2014 Renaissance Technologies Buys Stake in Pfizer; Yahoo Looks to Profit from Alibaba IPO
1
2
3
4
5
6
next >
PFE Pfizer, Inc. Research DD Guide
Stock Message Board http://investorshangout.com/search?q=PFE&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/PFE/quote
Stock Chart http://www.otcmarkets.com/stock/PFE/chart
Company Info http://www.otcmarkets.com/stock/PFE/company-info
Recent News http://www.otcmarkets.com/stock/PFE/news
Financials http://www.otcmarkets.com/stock/PFE/financials
Filings and Disclosure http://www.otcmarkets.com/stock/PFE/filings
Short Sales http://www.otcmarkets.com/stock/PFE/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/PFE/insider-transactions
Research Reports http://www.otcmarkets.com/stock/PFE/research
Summary http://finance.yahoo.com/q?s=PFE
Historical Prices http://finance.yahoo.com/q/hp?s=PFE+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=PFE
Basic Chart http://finance.yahoo.com/q/bc?s=PFE+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=PFE+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=PFE+Headlines
Press Releases http://finance.yahoo.com/q/p?s=PFE+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=PFE+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=PFE+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=PFE+Industry
Major Holders http://finance.yahoo.com/q/mh?s=PFE+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=PFE+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=PFE+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=PFE
Balance Sheet http://finance.yahoo.com/q/bs?s=PFE
Cash Flow http://finance.yahoo.com/q/cf?s=PFE+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/PFE
Market Watch http://www.marketwatch.com/investing/stock/PFE
Bloomberg http://www.bloomberg.com/quote/PFE:US
Morningstar http://quotes.morningstar.com/stock/s?t=PFE
Bussinessweek http://investing.businessweek.com/research/st...ticker=PFE
Barchart http://www.barchart.com/quotes/stocks/PFE
OTC Short Report http://otcshortreport.com/index.php?index=PFE
Investopedia http://www.investopedia.com/markets/stocks/PFE/?wa=0
Stock Message Board http://investorshangout.com/search?q=PFE&...mp;yt1=Go!
Last Updated: Sunday, March 30, 2014 9:21:01 PM
Pfizer, Inc. PFE Current Price and Quotes
Last Price 31.88
Previous Close 32.10 Open 32.20
Daily Range 32.48 - 31.74 52wk Range 32.96 - 27.12
Volume 21,969,900 Dividend 1.04
Average Vol (3m) 26,844,396 Yield 3.2622
Pfizer, Inc. PFE
Company Information
235 East 42nd Street
New York, NY 10017
Website: http://www.pfizer.com
Phone: (212) 573-2323
Pfizer, Inc. PFE
Not Available
Pfizer, Inc. PFE
Financial Reportings and Disclosures
Reporting Status U.S. Reporting: SEC Filer
Latest Report Dec 31, 2013 10-K
CIK 0000078003
Fiscal Year End 12/31
OTC Marketplace Not Available
Profile Data
SIC - Industry Classification Not Available
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Service Providers
Auditor/Accountant
Not Available
Legal Counsel
Not Available
Investor Relations Firm
Not Available
Pfizer, Inc. PFE
PFE Security Details
Share Structure
Market Value1 $199,338,758,462 a/o Mar 28, 2014
Shares Outstanding 6,382,925,343 a/o Feb 21, 2014
Float Not Available
Authorized Shares Not Available
Par Value 0.05
Shareholders
Shareholders of Record 231,737 a/o Feb 29, 2008
Corporate Actions
Ex. Date Record Date Pay Date
Dividend () Aug 14, 2002 Aug 16, 2002 Sep 05, 2002
Security Notes
Capital Change=shs increased by 2 for 1 split. Ex-date=07-03-95. Rec date=06-01-95. Pay date=06-30-95
Latest Secondary Issue=11-72, 703,447 shs at $43 by Lazard Freres & Co. et al.
Par Changed=10 cents to 5 cents. Basis: 2 for 1 split. Ex-date=07-03-95. Rec date=06-01-95. Pay date=06-30-95
Capital Change=Capital Change=shs increased by 3 for 1 split. . Ex-date=07/01/1999. Rec date=06/02/1999. Pay date=06/30/1999.
Short Selling Data
Short Interest (%)
Significant Failures to Deliver No
Transfer Agent(s)
Pfizer, Inc. PFE Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 51,584,000 54,657,000 61,035,000 65,165,000
Cost of Revenue 9,586,000 9,821,000 12,500,000 14,788,000
Gross Profit 41,998,000 44,836,000 48,535,000 50,377,000
Operating Expenses
Research and Development 6,678,000 7,482,000 8,681,000 9,483,000
Sales, General and Admin. 14,355,000 15,171,000 17,581,000 18,973,000
Non-Recurring Items 1,182,000 1,810,000 2,841,000 3,145,000
Other 4,599,000 5,109,000 5,465,000 5,364,000
Operating Income 15,184,000 15,264,000 13,967,000 13,412,000
Income From Continuing Operations
Add'l Income/Expense Items 532,000 (4,022,000) (2,486,000) (3,941,000)
Earnings Before Interest and Tax 15,716,000 11,242,000 11,481,000 9,471,000
Interest Expense - - - -
Earnings Before Tax 15,716,000 11,242,000 11,481,000 9,471,000
Income Tax 4,306,000 2,221,000 3,621,000 1,153,000
Minority Interest 69,000 28,000 40,000 31,000
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations 11,410,000 9,021,000 7,860,000 8,318,000
Non Recurring Events
Discontinued Operations 10,662,000 5,577,000 2,189,000 (30,000)
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 22,003,000 14,570,000 10,009,000 8,257,000
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 22,003,000 14,570,000 10,009,000 8,257,000
Pfizer, Inc. PFE Recent News
Mar 28, 2014 Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium(R) 24HR
Mar 28, 2014 Technical Summary on Active Stocks -- Research on Cisco Systems, Pfizer, Vale, and Advanced Micro Devices
Mar 28, 2014 Positive Opinions, Presentation Schedules of Investigational Data, Clinical Study Results, and Stock Price Movements - Analyst Notes on Johnson & Johnson, Merck, Pfizer, Amgen, and Allergan
Mar 27, 2014 In A Subanalysis, The Benefits Of Eliquis(R) (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control(1)
Mar 27, 2014 Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study(1)
Mar 26, 2014 Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN(R) In Very Young Children Born Small For Gestational Age
Mar 25, 2014 Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts
Mar 25, 2014 The Zacks Analyst Blog Highlights:Bristol-Myers Squibb, Pfizer, Alexion Pharmaceuticals, Gilead Sciences and AGCO
Mar 25, 2014 Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI(R) (crizotinib) Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Mar 25, 2014 Renaissance Technologies Buys Stake in Pfizer; Yahoo Looks to Profit from Alibaba IPO
1
2
3
4
5
6
next >
PFE Pfizer, Inc. Research DD Guide
Stock Message Board http://investorshangout.com/search?q=PFE&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/PFE/quote
Stock Chart http://www.otcmarkets.com/stock/PFE/chart
Company Info http://www.otcmarkets.com/stock/PFE/company-info
Recent News http://www.otcmarkets.com/stock/PFE/news
Financials http://www.otcmarkets.com/stock/PFE/financials
Filings and Disclosure http://www.otcmarkets.com/stock/PFE/filings
Short Sales http://www.otcmarkets.com/stock/PFE/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/PFE/insider-transactions
Research Reports http://www.otcmarkets.com/stock/PFE/research
Summary http://finance.yahoo.com/q?s=PFE
Historical Prices http://finance.yahoo.com/q/hp?s=PFE+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=PFE
Basic Chart http://finance.yahoo.com/q/bc?s=PFE+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=PFE+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=PFE+Headlines
Press Releases http://finance.yahoo.com/q/p?s=PFE+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=PFE+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=PFE+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=PFE+Industry
Major Holders http://finance.yahoo.com/q/mh?s=PFE+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=PFE+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=PFE+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=PFE
Balance Sheet http://finance.yahoo.com/q/bs?s=PFE
Cash Flow http://finance.yahoo.com/q/cf?s=PFE+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/PFE
Market Watch http://www.marketwatch.com/investing/stock/PFE
Bloomberg http://www.bloomberg.com/quote/PFE:US
Morningstar http://quotes.morningstar.com/stock/s?t=PFE
Bussinessweek http://investing.businessweek.com/research/st...ticker=PFE
Barchart http://www.barchart.com/quotes/stocks/PFE
OTC Short Report http://otcshortreport.com/index.php?index=PFE
Investopedia http://www.investopedia.com/markets/stocks/PFE/?wa=0
